 which is what is causing these shortages. What we have to realize is that this is not an economic thing worked out at a single drug level for a manufacturer, for a distributor, for anybody. It's a portfolio, it's an inventory. Generic companies make money by feeding on slightly higher prices as the drug erodes in that six, 12-month window immediately after the patent expiry. After that, it's a diminishing return. Those diminishing returns don't fund reinvestment in manufacturing capacity.